Serum uric acid as a marker of all-cause mortality in an elderly patient cohort
Utilidad del ácido úrico como marcador de mortalidad global en una cohorte de ancianos
Read
12377
Timeswas read the article
2670
Total PDF
9707
Total HTML
Share statistics
array:21 [ "pii" => "X2013251412000538" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Nov.11021" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:67-72" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6422 "formatos" => array:3 [ "EPUB" => 337 "HTML" => 5298 "PDF" => 787 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699512000530" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2011.Nov.11021" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2012;32:67-72" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 13111 "formatos" => array:3 [ "EPUB" => 284 "HTML" => 12045 "PDF" => 782 ] ] "es" => array:12 [ "idiomaDefecto" => true "titulo" => "Utilidad del ácido úrico como marcador de mortalidad global en una cohorte de ancianos" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "67" "paginaFinal" => "72" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Serum uric acid as a marker of all-cause mortality in an elderly patient cohort" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11021_108_18481_es_11021_t1.jpg" "Alto" => 332 "Ancho" => 567 "Tamanyo" => 135045 ] ] "descripcion" => array:1 [ "es" => "Niveles de ácido úrico (mg/dl) basal según género, antecedentes cardiovasculares y empleo de diuréticos" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "MANUEL HERAS, Manuel Heras, MARIA JOSE FERNANDEZ-REYES, María J. Fernández-Reyes, ROSA SANCHEZ, Rosa Sánchez, ALVARO MOLINA, Álvaro Molina, ASTRID RODRIGUEZ, Astrid Rodríguez, FERNANDO ALVAREZ-UDE, Fernando Álvarez-Ude" "autores" => array:12 [ 0 => array:2 [ "nombre" => "MANUEL" "apellidos" => "HERAS" ] 1 => array:2 [ "nombre" => "Manuel" "apellidos" => "Heras" ] 2 => array:2 [ "nombre" => "MARIA JOSE" "apellidos" => "FERNANDEZ-REYES" ] 3 => array:2 [ "nombre" => "María J." "apellidos" => "Fernández-Reyes" ] 4 => array:2 [ "nombre" => "ROSA" "apellidos" => "SANCHEZ" ] 5 => array:2 [ "nombre" => "Rosa" "apellidos" => "Sánchez" ] 6 => array:2 [ "nombre" => "ALVARO" "apellidos" => "MOLINA" ] 7 => array:2 [ "nombre" => "Álvaro" "apellidos" => "Molina" ] 8 => array:2 [ "nombre" => "ASTRID" "apellidos" => "RODRIGUEZ" ] 9 => array:2 [ "nombre" => "Astrid" "apellidos" => "Rodríguez" ] 10 => array:2 [ "nombre" => "FERNANDO" "apellidos" => "ALVAREZ-UDE" ] 11 => array:2 [ "nombre" => "Fernando" "apellidos" => "Álvarez-Ude" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251412000538" "doi" => "10.3265/Nefrologia.pre2011.Nov.11021" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000538?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000530?idApp=UINPBA000064" "url" => "/02116995/0000003200000001/v0_201502091357/X0211699512000530/v0_201502091357/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X201325141200052X" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Jul.10916" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:73-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6553 "formatos" => array:3 [ "EPUB" => 306 "HTML" => 5434 "PDF" => 813 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Bone mineral density and bone metabolism in hemodialysis patients. Correlation with PTH, 25OHD3 and leptin" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "73" "paginaFinal" => "78" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Densidad mineral y metabolismo óseo en pacientes en hemodiálisis. Correlación con la hormona paratifoidea, el 25(OH)D3 y la leptina" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "10916_16025_15578_en_t1_109163.jpg" "Alto" => 241 "Ancho" => 1060 "Tamanyo" => 118225 ] ] "descripcion" => array:1 [ "en" => "Demographic data in 18 female patients" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Polymeris, K. Doumouchtsis, E. Grapsa" "autores" => array:3 [ 0 => array:2 [ "Iniciales" => "A." "apellidos" => "Polymeris" ] 1 => array:2 [ "Iniciales" => "K." "apellidos" => "Doumouchtsis" ] 2 => array:2 [ "Iniciales" => "E." "apellidos" => "Grapsa" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512000522" "doi" => "10.3265/Nefrologia.pre2011.Jul.10916" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000522?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X201325141200052X?idApp=UINPBA000064" "url" => "/20132514/0000003200000001/v0_201502091620/X201325141200052X/v0_201502091620/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251412000546" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Oct.11031" "estado" => "S300" "fechaPublicacion" => "2012-01-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:59-66" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 5405 "formatos" => array:3 [ "EPUB" => 307 "HTML" => 4239 "PDF" => 859 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Early detection of chronic kidney disease: Collaboration of Belgrade nephrologists and primary care physicians" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "59" "paginaFinal" => "66" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Detección precoz de la enfermedad renal crónica: colaboración entre nefrólogos y especialistas de atención primaria de Belgrado" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11031_16025_18661_en_f111031.jpg" "Alto" => 663 "Ancho" => 1012 "Tamanyo" => 165471 ] ] "descripcion" => array:1 [ "en" => "Venn diagram presenting the distribution of patients depending on the presence of three risk factors" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ljubica Djukanović, Vi¿nja Lezaic, Nada Dimković, Gordana Peruničić Peković, Danica Bukvić, Sanja Bajčetić, Jelena Pavlović, Ana Bontić, Nade¿da Zec, Danijela Momčilović, Marina Stojanović" "autores" => array:11 [ 0 => array:2 [ "nombre" => "Ljubica" "apellidos" => "Djukanović" ] 1 => array:2 [ "nombre" => "Vi¿nja" "apellidos" => "Lezaic" ] 2 => array:2 [ "nombre" => "Nada" "apellidos" => "Dimković" ] 3 => array:2 [ "nombre" => "Gordana" "apellidos" => "Peruničić Peković" ] 4 => array:2 [ "nombre" => "Danica" "apellidos" => "Bukvić" ] 5 => array:2 [ "nombre" => "Sanja" "apellidos" => "Bajčetić" ] 6 => array:2 [ "nombre" => "Jelena" "apellidos" => "Pavlović" ] 7 => array:2 [ "nombre" => "Ana" "apellidos" => "Bontić" ] 8 => array:2 [ "nombre" => "Nade¿da" "apellidos" => "Zec" ] 9 => array:2 [ "nombre" => "Danijela" "apellidos" => "Momčilović" ] 10 => array:2 [ "nombre" => "Marina" "apellidos" => "Stojanović" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512000549" "doi" => "10.3265/Nefrologia.pre2011.Oct.11031" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000549?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000546?idApp=UINPBA000064" "url" => "/20132514/0000003200000001/v0_201502091620/X2013251412000546/v0_201502091620/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "titulo" => "Serum uric acid as a marker of all-cause mortality in an elderly patient cohort" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "67" "paginaFinal" => "72" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "MANUEL HERAS, Manuel Heras, MARIA JOSE FERNANDEZ-REYES, María J. Fernández-Reyes, ROSA SANCHEZ, Rosa Sánchez, ALVARO MOLINA, Álvaro Molina, ASTRID RODRIGUEZ, Astrid Rodríguez, FERNANDO ALVAREZ-UDE, Fernando Álvarez-Ude" "autores" => array:12 [ 0 => array:4 [ "nombre" => "MANUEL" "apellidos" => "HERAS" "email" => array:1 [ 0 => "mherasb@saludcastillayleon.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:4 [ "nombre" => "Manuel" "apellidos" => "Heras" "email" => array:1 [ 0 => "mherasb@saludcastillayleon.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 2 => array:3 [ "nombre" => "MARIA JOSE" "apellidos" => "FERNANDEZ-REYES" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 3 => array:3 [ "nombre" => "María J." "apellidos" => "Fernández-Reyes" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 4 => array:3 [ "nombre" => "ROSA" "apellidos" => "SANCHEZ" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 5 => array:3 [ "nombre" => "Rosa" "apellidos" => "Sánchez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 6 => array:3 [ "nombre" => "ALVARO" "apellidos" => "MOLINA" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 7 => array:3 [ "nombre" => "Álvaro" "apellidos" => "Molina" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 8 => array:3 [ "nombre" => "ASTRID" "apellidos" => "RODRIGUEZ" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 9 => array:3 [ "nombre" => "Astrid" "apellidos" => "Rodríguez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 10 => array:3 [ "nombre" => "FERNANDO" "apellidos" => "ALVAREZ-UDE" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 11 => array:3 [ "nombre" => "Fernando" "apellidos" => "Álvarez-Ude" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital General de Segovia, Spain, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital General de Segovia, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Utilidad del ácido úrico como marcador de mortalidad global en una cohorte de ancianos" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11021_108_25343_en_t1_11021i.jpg" "Alto" => 557 "Ancho" => 900 "Tamanyo" => 201512 ] ] "descripcion" => array:1 [ "en" => "Baseline levels of uric acid (mg/dl) according to gender, cardiovascular history and use of diuretics" ] ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">INTRODUCTION</span></p><p class="elsevierStylePara">Uric acid (UA), a waste product of purine metabolism, is degraded by urate oxidase (uricase) to allantoin, which is freely eliminated in urine. One of the consequences of the absence of uricase in humans is the appearance of higher levels of UA in humans than in other species. It may even reach plasma UA concentrations fifty times higher than in other mammals. This condition, far from being a drawback, has been postulated to be an evolutionary advance related to the protective ability of UA against oxidative damage of free radicals.<span class="elsevierStyleSup">1,2</span></p><p class="elsevierStylePara">Hyperuricaemia is generally defined by UA levels >6.5mg/dl or 7mg/dl in men and >6mg/dl in women.<span class="elsevierStyleSup">3</span></p><p class="elsevierStylePara">Although recent epidemiological studies have focused on gout, which has been increasing in prevalence particularly among elderly individuals, the studies suggest that the incidence of hyperuricaemia has also increased during this time.<span class="elsevierStyleSup">4</span></p><p class="elsevierStylePara">In addition to the role of UA in the onset of rheumatism and gout, it has been postulated for some time that it is a possible determinant of the onset of hypertension (AHT), diabetes mellitus and chronic kidney disease (CKD).<span class="elsevierStyleSup">2,5</span></p><p class="elsevierStylePara">In recent years, there has been growing evidence of a relationship between high levels of UA in blood and renal and cardiovascular disease, endothelial lesions being the proposed pathogenic mechanism.<span class="elsevierStyleSup">2,6</span></p><p class="elsevierStylePara">Prospective epidemiological studies have shown the association between baseline levels of UA and the incidence of CKD (with increasing risk as UA levels increase).<span class="elsevierStyleSup">7,8</span></p><p class="elsevierStylePara">Regarding cardiovascular comorbidity, some studies found an association between UA and increased risk of heart attacks and coronary ischaemic strokes. However, other studies have not confirmed these results in multivariate analyses.<span class="elsevierStyleSup">2</span></p><p class="elsevierStylePara">On the other hand, some studies have shown that UA levels behave as a risk factor for both cardiovascular and overall mortality.<span class="elsevierStyleSup">9</span> </p><p class="elsevierStylePara">In this study, we analysed the role of UA as an overall mortality marker in a cohort of elderly patients monitored for a period of 5 years. We also examined the association between baseline UA levels and cardiovascular history, the use of diuretics and renal function (RF).</p><p class="elsevierStylePara"><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">PATIENTS AND METHODS</span></p><p class="elsevierStylePara"><span class="elsevierStyleBold">Patients</span></p><p class="elsevierStylePara">This study was performed by analysing 5-year outcomes for a cohort of patients included in a study of elderly patients with CKD<span class="elsevierStyleSup">10,11,12</span> at the General Hospital of Segovia. Patients were recruited randomly while they visited the Geriatrics and General Nephrology departments during the period January-April 2006. Patients were in a period of clinical stability when they were selected and were monitored prospectively for 5 years (re-evaluation between January-April 2011). These patients had a mean age of 82.4±6 years (range 69-97 years) at baseline recruitment. Of these, 68.8% were women, 82.5% had histories of AHT, 35% were diabetic, 19.5% had histories of heart failure (HF), 15% had histories of ischaemic heart disease (IHD) and 68.4% were receiving diuretic therapy.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Laboratory analysis</span></p><p class="elsevierStylePara">A baseline analysis was performed one week before patients attended scheduled visits at the Geriatrics and Nephrology departments. According to the standard procedures of our hospital's laboratory, we measured creatinine, UA, albumin, cholesterol and triglycerides in venous blood. We also analysed creatinine and proteinuria in 24-hour urine (Nephrology visits) or in first morning urine (Geriatrics visits).</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Methods</span></p><p class="elsevierStylePara">This was a prospective observational study. Glomerular filtration rate (GFR) was calculated with the abbreviated MDRD formula.<span class="elsevierStyleSup">13</span> Based on the median baseline UA, we established two study groups: Group 1 consisting of 40 patients with UA <5.85mg/dl, and group 2 consisting of 40 patients with UA >5.85mg/dl. We also examined the possible association between high levels of UA (P75) and demographic characteristics, RF and mortality.</p><p class="elsevierStylePara">After five years, we analysed mortality according to study group.</p><p class="elsevierStylePara"><span class="elsevierStyleBold">Statistics</span></p><p class="elsevierStylePara">Statistical analysis was performed using the SPSS 15.0 program. Data are expressed as mean and standard deviation, or median and percentiles. Comparison of means was made with the Student's t-test and comparison of proportions with the chi-squared test. To analyse the simultaneous effect of several variables on mortality, we used a Cox analysis.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">RESULTS</span></p><p class="elsevierStylePara">UA showed a normal distribution. Mean baseline levels of UA were 6.11±1.7mg/dl (range 2.8-11) and their median was 5.85mg/dl (P25=4.90mg/dl, P75=7.07mg/dl). Regarding the use of diuretics, 42.6% used loop diuretics and 29.5% used thiazides. Potassium-sparing diuretics were the least prescribed, at a rate of 11.5%. Table 1 shows the association between uric acid levels and gender, cardiovascular history and use of diuretics. Patients with histories of HF had significantly higher levels of UA (7.00±1.74mg/dl vs 5.90±1.71mg/dl, <span class="elsevierStyleItalic">P</span>=.031).</p><p class="elsevierStylePara">Table 2 shows the comparison between demographic characteristics, RF parameters, comorbidity and mortality at 5 years, according to median UA. Patients with UA higher than the median had significantly lower GFR and higher mortality at 5 years.</p><p class="elsevierStylePara">Twenty patients had UA greater than P75 (7.07mg/dl). Table 3 compares the variables according to this percentile.</p><p class="elsevierStylePara">There were no patients lost to follow-up that were not due to death.</p><p class="elsevierStylePara">Overall, 41 patients died during the 5-year follow-up: 15 due to general deterioration, 8 due to infections, 4 due to stroke, 4 due to tumours, 3 due to cardiovascular problems, 2 due to fracture complications and 5 due to unknown reasons. In the multivariate Cox analysis, the only predictor of overall mortality after adjusting for age, gender, Charlson score, history of HF, use of diuretic and creatinine, presence of proteinuria and GFR-MDRD was UA level (mg/dl) (relative risk 1.35; 1.17-1.56; <span class="elsevierStyleItalic">P</span>=.000). Figures 1A and 1B show the Kaplan-Meier mortality curves according to the median uric acid and P75. Both figures show significantly higher mortality in patients with UA greater than P50 and P75.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">DISCUSSION</span></p><p class="elsevierStylePara">Overall mortality in the patient group with UA levels higher than the median was significantly higher. Moreover, if we analyse patients with UA levels >P75 (7.07mg/dl), their mortality increases even further, reaching 80%, results that are consistent with other recent studies.<span class="elsevierStyleSup">9</span></p><p class="elsevierStylePara">In this cohort of longer-lived patients, the most frequent cause of mortality was progressive deterioration rather than cardiovascular disease, and baseline UA levels were found to be the only predictors of mortality in the Cox analysis.</p><p class="elsevierStylePara">Hyperuricaemia has been linked to various diseases in humans.<span class="elsevierStyleSup">4</span> Gout is a disease that predominantly affects men, with an increase in prevalence in both genders as age increases. In our study, men also had higher levels of UA, although these differences were not significant, which may be due to the fact that we treated postmenopausal women in whom estrogenic activity had ceased.<span class="elsevierStyleSup">14</span></p><p class="elsevierStylePara">CKD has been associated with hyperuricaemia.<span class="elsevierStyleSup">2</span> In experimental studies in rats with hyperuricaemia, renal lesions included afferent arteriolopathy, mild interstitial fibrosis, glomerular hypertrophy and/or glomerulosclerosis.<span class="elsevierStyleSup">15</span> We also found in our study that elderly patients with greater levels of UA had significantly worse RF. This association may be valid in both directions, that is, the high levels of UA may be explained by renal ischaemia and reduced RF, and/or reduced GFR in patients with higher levels of UA may be due to the direct toxic effects of UA.</p><p class="elsevierStylePara">Diuretics, widely used to treat AHT with the additional benefit of preventing HF episodes,<span class="elsevierStyleSup">16</span> increase UA by stimulating the reabsorption of sodium and urate in the proximal tubule.<span class="elsevierStyleSup">3</span> Moreover, the increase in UA has also been observed in conditions that are accompanied by hypoxia (obstructive pulmonary disease, congestive HF).<span class="elsevierStyleSup">17,18</span> Leyva et al first studied UA concentrations in patients with chronic HF and found an inverse relationship between UA levels and oxygenation, suggesting that damage from oxidative metabolism may play a role in the pathogenesis of HF.<span class="elsevierStyleSup">19</span> In the SHEP study, diuretics were demonstrated to reduce cardiovascular mortality in the elderly. However, a recent subanalysis found that cardioprotection was lower in those patients who had high levels of UA.<span class="elsevierStyleSup">20</span></p><p class="elsevierStylePara">In our study, we found that UA levels were similar among those who received diuretics and those who did not. Moreover, elderly patients with histories of HF, who generally require higher doses of diuretics, had significantly greater levels of UA. It is therefore conceivable that the increase in UA levels in elderly patients with histories of HF is showing the effect of a local ischaemia rather than the increase associated with diuretics. Similarly, patients with history of IHD have higher levels of UA, although in this case it was not statistically significant, possibly due to the low number of patients who had this disease.</p><p class="elsevierStylePara">Lastly, ischaemia determines an increase in xanthine oxidase, which leads to an increase in UA levels.<span class="elsevierStyleSup">3</span> Treatment with xanthine oxidase inhibitors, such as allopurinol, has shown to reduce cardiovascular complications after coronary bypass and in patients with dilated cardiomyopathy.<span class="elsevierStyleSup">21</span> Recently, Goicoechea et al found that treatment with allopurinol in patients with chronic renal failure reduced the decline in RF.<span class="elsevierStyleSup">22</span> </p><p class="elsevierStylePara">With the data from our study, we cannot confirm that there is a causal relationship between high levels of UA and mortality. A step forward in our study would have been to confirm whether the reduction in UA levels with allopurinol, or more recently with febuxostat (a new inhibitor of the xanthine oxidase),<span class="elsevierStyleSup">23</span> contributes to reduced mortality in these patients.</p><p class="elsevierStylePara">An important prognostic factor of morbidity and mortality is the presence of proteinuria.<span class="elsevierStyleSup">24,25</span> In our follow-up study of RF in the elderly, the presence of proteinuria at 36 months was an independent factor of mortality.<span class="elsevierStyleSup">12</span> This did not occur in our analysis at five years, either proteinuria is included in the model as a qualitative variable (yes/no) or if its numerical value is used. This may be explained by the lack of proteinuria in the baseline sample and by the fact that the patients with higher proteinuria died in the first years of follow-up.</p><p class="elsevierStylePara">In conclusion, our data show that UA is an independent risk factor for overall mortality.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span><span class="elsevierStyleBold"> </span></p><p class="elsevierStylePara">The authors have no potential conflicts of interest to declare.</p><p class="elsevierStylePara"><a href="grande/11021_108_25343_en_t1_11021i.jpg" class="elsevierStyleCrossRefs"><img src="11021_108_25343_en_t1_11021i.jpg" alt="Baseline levels of uric acid (mg/dl) according to gender, cardiovascular history and use of diuretics"></img></a></p><p class="elsevierStylePara">Table 1. Baseline levels of uric acid (mg/dl) according to gender, cardiovascular history and use of diuretics</p><p class="elsevierStylePara"><a href="grande/11021_108_25344_en_t2_11021i.jpg" class="elsevierStyleCrossRefs"><img src="11021_108_25344_en_t2_11021i.jpg" alt="Comparison of variables according to the median uric acid (5.85mg/dl)"></img></a></p><p class="elsevierStylePara">Table 2. Comparison of variables according to the median uric acid (5.85mg/dl)</p><p class="elsevierStylePara"><a href="grande/11021_108_25345_en_t3_11021i.jpg" class="elsevierStyleCrossRefs"><img src="11021_108_25345_en_t3_11021i.jpg" alt="Comparison of variables according to P75 of uric acid (7.07mg/dl)"></img></a></p><p class="elsevierStylePara">Table 3. Comparison of variables according to P75 of uric acid (7.07mg/dl)</p><p class="elsevierStylePara"><a href="grande/11021_108_25346_en_f1_11021i.jpg" class="elsevierStyleCrossRefs"><img src="11021_108_25346_en_f1_11021i.jpg" alt="Kaplan-Meier mortality curve according to the median uric acid (P50)"></img></a></p><p class="elsevierStylePara">Figure 1A. Kaplan-Meier mortality curve according to the median uric acid (P50)</p><p class="elsevierStylePara"><a href="grande/11021_108_25347_en_f2_11021i.jpg" class="elsevierStyleCrossRefs"><img src="11021_108_25347_en_f2_11021i.jpg" alt="Kaplan-Meier mortality curve according to P75 of uric acid (P50)"></img></a></p><p class="elsevierStylePara">Figure 1B. Kaplan-Meier mortality curve according to P75 of uric acid (P50)</p>" "pdfFichero" => "P1-E532-S3377-A11021-EN.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:5 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec439115" "palabras" => array:1 [ 0 => "Enfermedad renal crónica" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec439117" "palabras" => array:1 [ 0 => "Ácido úrico" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec439119" "palabras" => array:1 [ 0 => "Ancianos" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec439121" "palabras" => array:1 [ 0 => "Filtrado glomerular" ] ] 4 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec439123" "palabras" => array:1 [ 0 => "Mortalidad" ] ] ] "en" => array:5 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec439116" "palabras" => array:1 [ 0 => "Chronic kidney disease" ] ] 1 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec439118" "palabras" => array:1 [ 0 => "Serum uric acid" ] ] 2 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec439120" "palabras" => array:1 [ 0 => "Elderly" ] ] 3 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec439122" "palabras" => array:1 [ 0 => "Glomerular filtration rate" ] ] 4 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec439124" "palabras" => array:1 [ 0 => "Mortality" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:1 [ "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Introducción</span><span class="elsevierStyleBold">:</span> Existe evidencia creciente del papel del ácido úrico (AU) como factor de riesgo cardiovascular y renal. En este trabajo analizamos la asociación entre niveles basales de AU y mortalidad global en una cohorte de ancianos seguidos prospectivamente durante 5 años. <span class="elsevierStyleBold">Pacientes y métodos</span><span class="elsevierStyleBold">:</span> 80 pacientes clínicamente estables; mediana de edad, 83 años (rango 69-97); 31,3% varones; 35% diabéticos; 83% hipertensos; reclutados aleatoriamente en consultas de Geriatría y Nefrología entre enero y abril de 2006 y seguidos durante 5 años. Medimos basalmente AU y creatinina en plasma y estimamos filtrado glomerular (FG) con fórmula MDRD abreviada. Asimismo, en los pacientes de Nefrología se midió la proteinuria mediante la recogida de orina de 24 horas, y en los vistos en Geriatría se estimó a partir del cociente proteínas (mg/dl)/creatinina (mg/dl) en primera orina de la mañana. Registramos edad, género, comorbilidad basal (Índice de Charlson), patologías cardiovasculares individualizadas, tratamientos y mortalidad. Estadística: SPSS15.0. <span class="elsevierStyleBold">Resultados</span><span class="elsevierStyleBold">:</span> El AU basal presentaba una distribución normal y su mediana era de 5,85 mg/dl. No encontramos diferencias significativas en los niveles de AU según género, antecedentes de diabetes méllitus, hipertensión arterial, uso de diuréticos, cardiopatía isquémica, arteriopatía periférica o ictus. Los pacientes con antecedentes de insuficiencia cardíaca tenían AU significativamente mayor (7,00 ± 1,74 vs. 5,90 ± 1,71; p = 0,031). 41 pacientes (15 varones y 26 mujeres) fallecieron: 15 por deterioro en el estado general; 8 por infecciones; 4 por ictus; 4 por tumores; 3 por causas cardiovasculares; 2 por complicaciones de fracturas y 5 por causas desconocidas. Los pacientes con AU superior a la mediana tenían un FG significativamente menor y una mortalidad a los 5 años más elevada. En el análisis de Cox para mortalidad global (variables independientes: edad, género, Charlson, antecedentes de insuficiencia cardíaca, AU, creatinina, proteinuria y filtrado glomerular-MDRD) sólo los niveles de AU (riesgo relativo: 1,35; 1,17-1,56, p = 0,000) se asociaban de forma independiente a la mortalidad. <span class="elsevierStyleBold">Conclusiones</span><span class="elsevierStyleBold">:</span> en nuestro estudio, los niveles de AU se muestran como factor de riesgo independiente de mortalidad en ancianos.</p>" ] "en" => array:1 [ "resumen" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">Introduction:</span> There is growing evidence of the role of serum uric acid (SUA) as a risk factor for cardiovascular and renal disease. We analysed the association between baseline SUA and overall mortality in a cohort of elderly patients followed prospectively for 5 years. <span class="elsevierStyleBold">Patients and Methods:</span> Eighty clinically stable patients, median age 83 years (range 69-97), 31.3% men, 35% diabetics, 83% hypertensives were randomly recruited at Geriatrics and Nephrology visits between January and April 2006 and followed for 5 years. We measured baseline SUA and serum creatinine and estimated glomerular filtration rate (GFR) with MDRD abbreviated. In Nephrology Department patients, we measured proteinuria in 24-hour urine and in Geriatrics department patients we measured proteinuria (mg/dl)/creatinine (mg/dl) in urine (first morning urine). Predictive variables were: baseline SUA and plasma creatinine; estimated GFR (abbreviated MDRD formula); and we recorded age, gender, baseline comorbidity (Charlson index), individualised cardiovascular treatment and mortality. Statistical analysis: SPSS15.0. <span class="elsevierStyleBold">Results:</span> baseline SUA was normally distributed and its median was 5.85mg/dl. We found no significant differences in levels of SUA by gender, history of diabetes mellitus, hypertension, diuretic drug use, heart disease, peripheral arterial disease or stroke. Patients with a history of heart failure had significantly higher SUA (7.00±1.74 vs 5.90±1.71, <span class="elsevierStyleItalic">P</span>=.031). Some 41 deaths occurred during follow-up (15 men and 26 women): 15 due to general deterioration, 8 due to infections, 4 due to stroke, 4 due to tumours, 3 due to cardiovascular disease, 2 due to complications of fractures and 5 due to unknown causes. Patients with SUA higher than the median had significantly lower GFR and higher mortality at 5 years. In the Cox analysis for overall mortality [independent variables: age, gender, Charlson Index, history of heart failure, SUA, creatinine, proteinuria and GFR (MDRD)] only SUA levels (HR: 1.35; 1.17-1.56 <span class="elsevierStyleItalic">P</span>=.000) were independently associated with mortality. <span class="elsevierStyleBold">Conclusions:</span> In our study, levels of SUA are an independent risk factor for mortality in elderly patients.</p>" ] ] "multimedia" => array:5 [ 0 => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11021_108_25343_en_t1_11021i.jpg" "Alto" => 557 "Ancho" => 900 "Tamanyo" => 201512 ] ] "descripcion" => array:1 [ "en" => "Baseline levels of uric acid (mg/dl) according to gender, cardiovascular history and use of diuretics" ] ] 1 => array:8 [ "identificador" => "fig2" "etiqueta" => "Tab. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11021_108_25344_en_t2_11021i.jpg" "Alto" => 335 "Ancho" => 900 "Tamanyo" => 188719 ] ] "descripcion" => array:1 [ "en" => "Comparison of variables according to the median uric acid (5.85mg/dl)" ] ] 2 => array:8 [ "identificador" => "fig3" "etiqueta" => "Tab. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11021_108_25345_en_t3_11021i.jpg" "Alto" => 344 "Ancho" => 900 "Tamanyo" => 171714 ] ] "descripcion" => array:1 [ "en" => "Comparison of variables according to P75 of uric acid (7.07mg/dl)" ] ] 3 => array:8 [ "identificador" => "fig4" "etiqueta" => "Fig. 1A" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11021_108_25346_en_f1_11021i.jpg" "Alto" => 900 "Ancho" => 900 "Tamanyo" => 227058 ] ] "descripcion" => array:1 [ "en" => "Kaplan-Meier mortality curve according to the median uric acid (P50)" ] ] 4 => array:8 [ "identificador" => "fig5" "etiqueta" => "Fig. 1B" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11021_108_25347_en_f2_11021i.jpg" "Alto" => 772 "Ancho" => 900 "Tamanyo" => 208041 ] ] "descripcion" => array:1 [ "en" => "Kaplan-Meier mortality curve according to P75 of uric acid (P50)" ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003200000001/v0_201502091620/X2013251412000538/v0_201502091620/en/main.assets" "Apartado" => array:4 [ "identificador" => "35441" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Originals" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000001/v0_201502091620/X2013251412000538/v0_201502091620/en/P1-E532-S3377-A11021-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000538?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 8 | 11 | 19 |
| 2024 October | 45 | 51 | 96 |
| 2024 September | 55 | 53 | 108 |
| 2024 August | 81 | 63 | 144 |
| 2024 July | 35 | 45 | 80 |
| 2024 June | 72 | 46 | 118 |
| 2024 May | 56 | 49 | 105 |
| 2024 April | 51 | 35 | 86 |
| 2024 March | 41 | 19 | 60 |
| 2024 February | 42 | 34 | 76 |
| 2024 January | 31 | 26 | 57 |
| 2023 December | 24 | 18 | 42 |
| 2023 November | 36 | 33 | 69 |
| 2023 October | 110 | 30 | 140 |
| 2023 September | 124 | 37 | 161 |
| 2023 August | 82 | 25 | 107 |
| 2023 July | 113 | 51 | 164 |
| 2023 June | 86 | 28 | 114 |
| 2023 May | 166 | 40 | 206 |
| 2023 April | 77 | 24 | 101 |
| 2023 March | 69 | 22 | 91 |
| 2023 February | 43 | 19 | 62 |
| 2023 January | 62 | 29 | 91 |
| 2022 December | 55 | 33 | 88 |
| 2022 November | 56 | 31 | 87 |
| 2022 October | 58 | 46 | 104 |
| 2022 September | 38 | 32 | 70 |
| 2022 August | 63 | 57 | 120 |
| 2022 July | 70 | 50 | 120 |
| 2022 June | 67 | 35 | 102 |
| 2022 May | 69 | 24 | 93 |
| 2022 April | 84 | 47 | 131 |
| 2022 March | 87 | 48 | 135 |
| 2022 February | 86 | 46 | 132 |
| 2022 January | 157 | 29 | 186 |
| 2021 December | 79 | 46 | 125 |
| 2021 November | 88 | 39 | 127 |
| 2021 October | 131 | 39 | 170 |
| 2021 September | 93 | 44 | 137 |
| 2021 August | 88 | 40 | 128 |
| 2021 July | 84 | 26 | 110 |
| 2021 June | 103 | 36 | 139 |
| 2021 May | 134 | 40 | 174 |
| 2021 April | 186 | 90 | 276 |
| 2021 March | 118 | 37 | 155 |
| 2021 February | 134 | 18 | 152 |
| 2021 January | 85 | 23 | 108 |
| 2020 December | 99 | 12 | 111 |
| 2020 November | 54 | 16 | 70 |
| 2020 October | 43 | 13 | 56 |
| 2020 September | 68 | 6 | 74 |
| 2020 August | 63 | 13 | 76 |
| 2020 July | 58 | 11 | 69 |
| 2020 June | 72 | 18 | 90 |
| 2020 May | 69 | 12 | 81 |
| 2020 April | 77 | 13 | 90 |
| 2020 March | 55 | 14 | 69 |
| 2020 February | 82 | 24 | 106 |
| 2020 January | 72 | 29 | 101 |
| 2019 December | 56 | 23 | 79 |
| 2019 November | 42 | 23 | 65 |
| 2019 October | 24 | 12 | 36 |
| 2019 September | 42 | 23 | 65 |
| 2019 August | 39 | 10 | 49 |
| 2019 July | 51 | 27 | 78 |
| 2019 June | 65 | 18 | 83 |
| 2019 May | 66 | 17 | 83 |
| 2019 April | 103 | 33 | 136 |
| 2019 March | 60 | 24 | 84 |
| 2019 February | 43 | 20 | 63 |
| 2019 January | 47 | 24 | 71 |
| 2018 December | 157 | 42 | 199 |
| 2018 November | 132 | 20 | 152 |
| 2018 October | 147 | 16 | 163 |
| 2018 September | 124 | 23 | 147 |
| 2018 August | 103 | 22 | 125 |
| 2018 July | 93 | 15 | 108 |
| 2018 June | 88 | 23 | 111 |
| 2018 May | 83 | 26 | 109 |
| 2018 April | 97 | 10 | 107 |
| 2018 March | 81 | 17 | 98 |
| 2018 February | 73 | 6 | 79 |
| 2018 January | 78 | 11 | 89 |
| 2017 December | 82 | 11 | 93 |
| 2017 November | 87 | 20 | 107 |
| 2017 October | 56 | 11 | 67 |
| 2017 September | 53 | 13 | 66 |
| 2017 August | 43 | 9 | 52 |
| 2017 July | 51 | 13 | 64 |
| 2017 June | 46 | 12 | 58 |
| 2017 May | 59 | 20 | 79 |
| 2017 April | 50 | 13 | 63 |
| 2017 March | 40 | 15 | 55 |
| 2017 February | 45 | 26 | 71 |
| 2017 January | 33 | 13 | 46 |
| 2016 December | 86 | 11 | 97 |
| 2016 November | 100 | 16 | 116 |
| 2016 October | 154 | 19 | 173 |
| 2016 September | 225 | 15 | 240 |
| 2016 August | 314 | 17 | 331 |
| 2016 July | 236 | 6 | 242 |
| 2016 June | 161 | 0 | 161 |
| 2016 May | 139 | 0 | 139 |
| 2016 April | 101 | 0 | 101 |
| 2016 March | 130 | 0 | 130 |
| 2016 February | 124 | 0 | 124 |
| 2016 January | 132 | 0 | 132 |
| 2015 December | 137 | 0 | 137 |
| 2015 November | 107 | 0 | 107 |
| 2015 October | 117 | 0 | 117 |
| 2015 September | 100 | 0 | 100 |
| 2015 August | 80 | 0 | 80 |
| 2015 July | 66 | 0 | 66 |
| 2015 June | 40 | 0 | 40 |
| 2015 May | 67 | 0 | 67 |
| 2015 April | 18 | 0 | 18 |
Show all
